Coherus Biosciences Inc (NASDAQ:CHRS) currently has a daily average trading volume of 2.82M but it saw 3270719 shares traded in last market. With a market cap of 142.90M USD, the company’s current market price of $1.26 came falling about -1.56 while comparing to the previous closing price of $1.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.70 and as low as $0.66. In the recent trading on the day, stock has struck highest price mark of $1.23 while lowest mark touched by it was $1.35.
Taking a look at 20-day trading activity of Coherus Biosciences Inc (CHRS) gives us an average price of $0.8884, while its current price level is -65.95% below from 52-week high level whereas it is 90.82% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.9220 while that of 200 days or SMA-200 reads an average of $1.6339. A closer look into the stock’s movement over the week reveals that its volatility is standing at 14.31% during that period while stretching the period over a month that decreases to 13.11%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 73.88 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the UBS which downgraded the stock as “Neutral” in its note to investors issued on August 16, 2024, recommending a price target of between $4 and $1.50 for it.
Over the week, CHRS’s stock price is moving 14.55% up while it is 69.49% when we observe its performance for the past one month. Year-to-date it is -62.16% down and over the past year, the stock is showing a downside performance of -40.28%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.62 beaten by the consensus estimate of -0.1 for the same. The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.18 while estimate for next year EPS is -1.0. In next quarter, company is expected to be making quarterly sales of $66.55M as analysts are expecting the sales for current fiscal year at $255.58M and seeing the company making $286.76M in sales next year. Moreover, analysts are in estimates of $43.88M for current-quarter revenue.
Currently, Coherus Biosciences Inc’s total number of outstanding shares is 112.22M with 1.39% of that held by the insiders while 70.10% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -0.22%. Stock’s beta reads 0.88. Stock has a price to sale or P/S ratio amounts to 0.47. Its return on asset (ROA) is -0.08% on average.
